Nonfasting Lipid Testing Gains Growing Acceptance
Although fasting before a lipid test has long been recommended, a new study and accompanying commentaries make the case that nonfasting lipid levels are acceptable and may even be superior to fasting...
View ArticleFDA Approves Lomitapide for Homozygous Familial Hypercholesterolemia
Aegerion Pharmaceuticals said today that the FDA had approved lomitapide (Juxtapid) to help further lower cholesterol in patients with homozygous familial hypercholesterolemia. The approval comes with...
View ArticleHPS2-THRIVE: A ‘Disappointing But Clear’ Result
For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the...
View ArticleClik here to view.
FDA Approves Combination of Ezetimibe and Atorvastatin
The FDA has approved a new combination drug from Merck for lowering cholesterol. The drug, which will carry the brand name of Liptruzet, is a combination of two previously approved cholesterol-lowering...
View ArticlePreliminary Outcomes Results For PCSK9 Inhibitor
Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol—drastically and in a wide variety of different patient populations—data from one trial offers the first...
View ArticleGenetic Study Suggests Possible Causal Role for LDL in Aortic Valve Disease
Although LDL is an important risk factor for aortic valve disease, the precise role it plays has been uncertain. Lipid-lowering therapy in people with established aortic valve disease has not been...
View ArticleNewly Identified Mutations Act Like a Lifetime of Treatment with Ezetimibe
A very large genetic study published in the New England Journal of Medicine offers compelling evidence in support of a central role for LDL cholesterol in coronary heart disease. In a series of studies...
View ArticleIMPROVE-IT Meets Endpoint and Demonstrates Real But Modest Clinical Benefit...
After all the waiting and all the controversy it turned out to be pretty simple. The IMPROVE-IT trial did what it set out to do and reached its primary endpoint. The benefit wasn’t very big or...
View ArticleMore Information Emerges About the PCSK9 Inhibitors
New information emerged today about two new cholesterol-lowering drugs that have been attracting a lot of attention. Data about the PCSK9 inhibitors — evolocumab, under development by Amgen, and...
View ArticleMore Preliminary Signs That PCSK9 Inhibitors May Improve Outcomes
A new analysis of available data from early trials with PCSK9 inhibitors adds to the growing evidence showing that this much-anticipated new class of drugs dramatically lowers LDL cholesterol and...
View Article
